LACTOLOGY FOUNDATION

Propulsives (ATC A03FA) are prokinetic agents that enhance gastrointestinal motility and are used mainly for functional gastrointestinal disorders such as gastroparesis, reflux, dyspepsia and functional bowel complaints. From a toxico‑lactological perspective, most classical A03FA agents can be used with caution in breastfeeding, but domperidone and metoclopramide warrant particular attention because of central nervous system (CNS) and cardiac risks and their off‑label use as galactagogues.atcddd.fhi+3

ATC class overview

The ATC subgroup A03FA (Propulsives) sits within A03 “Drugs for functional gastrointestinal disorders” in the Alimentary tract and metabolism group. It includes dopamine D2 antagonists and related benzamides that stimulate gastrointestinal motility, primarily in the upper GI tract.drugbank+3

Agents in this class are used to relieve symptoms such as nausea, vomiting, early satiety, bloating and constipation in conditions like gastroparesis, functional dyspepsia and irritable bowel syndrome with slow transit. In clinical practice, prokinetics are often combined with acid‑suppressive therapy or dietary measures, and some drugs (for example cisapride) have been withdrawn or heavily restricted because of serious cardiac toxicity.pmc.ncbi.nlm.nih+2

Representative substances in A03FA

According to the current ATC index, the core substances in A03FA are metoclopramide (A03FA01), cisapride (A03FA02), domperidone (A03FA03), bromopride (A03FA04), alizapride (A03FA05), clebopride (A03FA06) and itopride (A03FA07). All are propulsive agents but differ in receptor profile, degree of central penetration and safety signal profile, which is crucial for lactation risk stratification.atcddd.fhi+2

Metoclopramide, domperidone and cisapride are historically the most clinically relevant worldwide, with domperidone and metoclopramide also used off‑label as galactagogues due to their prolactin‑raising effect. Itopride is a newer benzamide combining D2 antagonism with acetylcholinesterase inhibition, typically marketed for functional dyspepsia and sometimes preferred where available because it appears to have fewer CNS effects than metoclopramide.medsafe+3

Mechanism of action and pharmacology

Classical benzamide prokinetics such as metoclopramide, domperidone, bromopride, alizapride, clebopride and itopride act primarily through dopamine D2 receptor antagonism, which enhances cholinergic activity in the enteric nervous system and thereby accelerates gastric emptying and small‑intestinal transit. Metoclopramide and some congeners also exert weak 5‑HT4 agonism and 5‑HT3 antagonism, which contributes to their antiemetic effect in the chemoreceptor trigger zone.litfl+3

Cisapride is a prokinetic with strong 5‑HT4 agonist activity and minimal dopaminergic activity, increasing acetylcholine release in the myenteric plexus but with a high propensity for QT‑interval prolongation and torsades de pointes, which led to its withdrawal or restriction in many countries. The pharmacokinetic profiles of these agents (oral bioavailability, protein binding, half‑life) vary and are key determinants of both systemic toxicity and infant exposure via breast milk, favouring short‑acting, highly protein‑bound compounds in lactating patients.slideshare+5

General toxicological profile

The class‑typical adverse effects of D2‑antagonist prokinetics include extrapyramidal symptoms (acute dystonia, akathisia, Parkinsonism), hyperprolactinaemia and associated endocrine effects, and, less commonly, tardive dyskinesia with prolonged exposure. Sedation, restlessness, diarrhoea, abdominal cramps and, in susceptible individuals, mood changes or depression may also occur.australianprescriber.tg+3

Cisapride’s toxicity profile is dominated by cardiac arrhythmias due to QT prolongation, particularly in the presence of CYP3A4 inhibitors, electrolyte disturbances or pre‑existing cardiac disease, which is why its use is now highly restricted or discontinued in many settings. Domperidone, while largely peripherally acting and considered to have fewer CNS adverse effects than metoclopramide, also carries a signal for QT prolongation and serious ventricular arrhythmias, especially at higher doses or in older patients and those with cardiac risk factors.pmc.ncbi.nlm.nih+3

Toxicity and risk factors in mothers

In adult patients, risk factors for serious adverse events from A03FA agents include prolonged high‑dose therapy, concomitant QT‑prolonging drugs, electrolyte disturbances, hepatic or renal impairment and underlying movement disorders. Young women may be particularly susceptible to acute dystonic reactions with metoclopramide and related centrally acting benzamides, especially with parenteral administration.litfl+2

For domperidone and cisapride, careful evaluation of baseline and follow‑up ECGs, correction of hypokalaemia and avoidance of potent CYP3A4 inhibitors are recommended risk‑mitigation measures where these drugs remain available. When A03FA agents are considered in the postpartum period, added vigilance is needed because peripartum fluid shifts, anaemia and co‑medication (for example antiemetics, antidepressants) may amplify both CNS and cardiac risk.mayoclinic+4

Lactation‑specific general considerations

Most medicines taken orally by the mother appear in breast milk in small amounts, and in general exposures below 10% of the maternal weight‑adjusted dose are often considered compatible with breastfeeding when the drug has no inherent severe toxicity. In line with general lactation pharmacology principles, drugs with short half‑lives, high maternal protein binding, low oral bioavailability and higher molecular weight are preferred.racgp+2

Regardless of the specific A03FA agent chosen, breastfeeding infants should be monitored for sedation, irritability, feeding difficulties and gastrointestinal disturbances such as diarrhoea or colic, which are among the more commonly observed reactions to maternal medication exposure. Timing the maternal dose immediately after a feed and avoiding unnecessary prolonged treatment can further reduce infant exposure.medsafe+2

Metoclopramide (A03FA01)

Metoclopramide is a centrally and peripherally acting D2 antagonist with additional 5‑HT3 antagonism and weak 5‑HT4 agonism, used for nausea, vomiting and motility disorders such as gastroparesis. It crosses the blood–brain barrier and is associated with extrapyramidal reactions, especially in young adults and with parenteral use, as well as hyperprolactinaemia.slideshare+1

As a galactagogue, metoclopramide increases prolactin and breast‑milk production but only modestly in clinical trials, and its neuropsychiatric side‑effect profile (including potential for depression and tardive dyskinesia) limits its use. For lactating mothers who require metoclopramide as an antiemetic or prokinetic, short‑course therapy at the lowest effective dose is generally preferred, with monitoring of the infant for sedation, feeding difficulties and abnormal movements.australianprescriber.tg+2

Cisapride (A03FA02)

Cisapride is a 5‑HT4 agonist prokinetic that enhances acetylcholine release in the myenteric plexus, promoting esophageal and gastric motility and previously used for severe reflux and gastroparesis. Its use has been largely curtailed worldwide because of serious ventricular arrhythmias and sudden death associated with QT prolongation, especially in combination with CYP3A4 inhibitors.pmc.ncbi.nlm.nih+2

Data in breastfeeding are limited, but given its cardiac risk profile and the availability of safer alternatives, cisapride is generally avoided in lactating women except possibly in exceptional cases under specialist supervision. If exposure occurs, it would be prudent to monitor the infant for poor feeding, lethargy, cyanosis or arrhythmia symptoms and to avoid any other QT‑prolonging co‑medications in the mother.mayoclinic+2

Domperidone (A03FA03)

Domperidone is a peripheral D2 antagonist with limited penetration of the blood–brain barrier, used to treat nausea, vomiting and motility disorders and widely studied as a galactagogue due to its prolactin‑stimulating action. It is associated with fewer CNS adverse effects than metoclopramide, but regulatory authorities have issued warnings about increased risk of QT prolongation and serious ventricular arrhythmias, particularly at higher cumulative doses.drugbank+3

As a galactagogue, domperidone produces modest increases in milk volume in some studies, but guidelines emphasise that its off‑label use should be time‑limited, at the lowest effective dose, and preceded by optimisation of non‑pharmacological lactation support. When used in breastfeeding mothers for either GI indications or for milk‑supply augmentation, maternal cardiac risk factors and interacting medicines should be carefully assessed, and infants observed for sedation, GI upset or feeding changes, although milk levels are typically low.racgp+2

Bromopride, alizapride and clebopride (A03FA04–A03FA06)

Bromopride, alizapride and clebopride are benzamide derivatives with D2‑antagonist prokinetic and antiemetic properties, pharmacologically similar to metoclopramide but with variable central penetration and regional availability. They may cause extrapyramidal reactions, hyperprolactinaemia and gastrointestinal side effects, with risk patterns broadly analogous to other centrally acting benzamides.drugbank+2

Specific lactation data for these molecules are limited, so risk assessment is generally extrapolated from their pharmacological class and known toxicity in adults. Short‑term use in breastfeeding women may be acceptable when clearly indicated, but centrally acting agents are usually avoided as first‑line options if safer local alternatives (for example more peripherally acting drugs) are available, particularly in neonates and premature infants.medsafe+2

Itopride (A03FA07)

Itopride combines peripheral D2 antagonism with acetylcholinesterase inhibition, enhancing gastric emptying and intestinal motility and used mainly for functional dyspepsia. Because of its limited central penetration, it may have a lower incidence of CNS adverse effects compared with metoclopramide, though cholinergic‑related GI effects such as diarrhoea and abdominal discomfort can occur.drugbank+1

Published information on itopride use during breastfeeding is sparse, but its pharmacokinetic characteristics (peripheral action and absence of major arrhythmia signals to date) are sometimes considered favourable relative to older prokinetics. In the absence of robust lactation data, it should still be used cautiously in nursing mothers, preferring minimal effective dosing, limited duration and infant monitoring for GI intolerance or unusual symptoms.racgp+4

Practical lactation risk stratification within A03FA

For a toxico‑lactological database, A03FA agents can be broadly stratified as follows, assuming usual therapeutic dosing in an otherwise healthy mother:

·        Relatively more favourable (with monitoring): domperidone, metoclopramide, itopride – short courses, careful attention to maternal cardiac or neuropsychiatric risk and infant observation.australianprescriber.tg+3

·        Cautious/limited data: bromopride, alizapride, clebopride – consider when benefits clearly outweigh risks, avoiding prolonged central D2 antagonism in the postpartum period.pmc.ncbi.nlm.nih+2

·        Generally unfavourable in lactation: cisapride – largely avoided due to serious maternal cardiac toxicity and lack of reassuring infant‑exposure data.litfl+1

Across the class, key risk‑reduction strategies in breastfeeding include choosing agents with better safety records, using the lowest effective dose for the shortest time, timing doses after feeds and monitoring both mother and infant for neurological, cardiac or gastrointestinal adverse effects. Decisions should always balance the benefits of treating the maternal GI condition (which may itself interfere with breastfeeding) against the theoretical and observed risks of the drug to the infant.mayoclinic+3